Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | CDH1 | P12830 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9114614 | 0.85 | SMN1; SMN2 (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL544183 | 0.84 | PTPN1 (0.47) | NPC1RAB9AALDH1A1TDO2TP53 | |
| SCHEMBL3180927 | 0.83 | BCL2L1 (0.44) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3173623 | 0.83 | SMN1; SMN2 (0.46) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL343121 | 0.83 | PTPN1 (0.46) | ALDH1A1KDM4E | |
| SCHEMBL3178747 | 0.81 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2MAPTTDO2 | |
| SCHEMBL20507173 | 0.81 | SLC6A3 (0.51) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL9115919 | 0.80 | RAB9A (0.44) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL3541658 | 0.79 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3546598 | 0.79 | ALDH1A1 (0.56) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | claimed |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | IPS HEART | 2021-02-25 | — | — | US | disclosed |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | disclosed |
| CN-101910160-A | Isoxazole derivatives as modulators of 11-beta-hydroxysteroid dehydrogenase type 1 | BIOVITRUM AB PUBL | 2010-12-08 | — | — | CN | disclosed |
| EP-2231650-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Biovitrum AB (publ) (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20100022590-A1 | Novel compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-01-28 | — | — | US | disclosed |
| WO-2009090239-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (PUBL) (SE) | 2009-07-23 | — | — | WO | disclosed |
| EP-2051977-A2 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1 | Amgen Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008011453-A2 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 | AMGEN INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | HSD17B1, HSD11B1, HSD17B11 | NPC1 1594/4885RAB9A 2914/4885SMN1; SMN2 3710/4885 |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | EXOSC9, EXOSC5, EXOSC4 | NPC1 1167/4885RAB9A 334/4885SMN1; SMN2 14/4885 |
| US-20100022590-A1 | Novel compounds | HSD11B1, CYP11B1, HSD11B2 | NPC1 639/4885RAB9A 2623/4885SMN1; SMN2 3935/4885 |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | EXOSC5, UTRN, EXOSC4 | NPC1 2053/4885RAB9A 2257/4885SMN1; SMN2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.